E Fund Management Co., Ltd. Bei Gene, Ltd. Transaction History

E Fund Management Co., Ltd.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$131.8 - $202.24 $34,004 - $52,177	-258 Reduced 0.8%	31,961 $4.31 Million
Q2 2022 Aug 15, 2022	BUY	$121.11 - $216.05 $3.9 Million - $6.96 Million	32,219 New	32,219 $5.22 Million
Q1 2022 May 12, 2022	SELL	$146.52 - $269.56 $1.7 Million - $3.12 Million	-11,572 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$248.56 - $389.34 $2.88 Million - $4.51 Million	11,572 New	11,572 $3.14 Million

253

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $23.5B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of E Fund Management Co., Ltd., based on Form 13F filings with the SEC.

Stay updated on E Fund Management Co., Ltd. with notifications on news.